MX354249B - Formas de dosificación farmacéuticas intranasales que comprenden naloxona. - Google Patents

Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Info

Publication number
MX354249B
MX354249B MX2013013276A MX2013013276A MX354249B MX 354249 B MX354249 B MX 354249B MX 2013013276 A MX2013013276 A MX 2013013276A MX 2013013276 A MX2013013276 A MX 2013013276A MX 354249 B MX354249 B MX 354249B
Authority
MX
Mexico
Prior art keywords
naloxone
pharmaceutical dosage
intranasal pharmaceutical
dosage forms
dosage form
Prior art date
Application number
MX2013013276A
Other languages
English (en)
Spanish (es)
Other versions
MX2013013276A (es
Inventor
Strang John
Oksche Alexander
Harris Stephen
Smith Kevin
Helene Jeanne Mottier Lucie
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44658496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX354249(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MX2013013276A publication Critical patent/MX2013013276A/es
Publication of MX354249B publication Critical patent/MX354249B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2013013276A 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona. MX354249B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166076 2011-05-13
PCT/EP2012/058792 WO2012156317A2 (en) 2011-05-13 2012-05-11 Intranasal pharmaceutical dosage forms comprising naloxone

Publications (2)

Publication Number Publication Date
MX2013013276A MX2013013276A (es) 2014-08-07
MX354249B true MX354249B (es) 2018-02-20

Family

ID=44658496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013276A MX354249B (es) 2011-05-13 2012-05-11 Formas de dosificación farmacéuticas intranasales que comprenden naloxona.

Country Status (37)

Country Link
US (7) US20150018379A1 (enExample)
EP (2) EP3320893A1 (enExample)
JP (3) JP6110367B2 (enExample)
KR (2) KR101873174B1 (enExample)
CN (2) CN107260672A (enExample)
AR (1) AR086391A1 (enExample)
AT (1) AT16553U1 (enExample)
AU (2) AU2012257785B2 (enExample)
BR (1) BR112013029126A2 (enExample)
CA (1) CA2835940C (enExample)
CO (1) CO6821959A2 (enExample)
CY (1) CY1120399T1 (enExample)
DE (1) DE202012013606U1 (enExample)
DK (2) DK2706982T4 (enExample)
ES (1) ES2661838T5 (enExample)
HK (1) HK1255428A1 (enExample)
HR (1) HRP20180233T1 (enExample)
HU (1) HUE036465T2 (enExample)
IL (1) IL229409B (enExample)
LT (1) LT2706982T (enExample)
ME (1) ME02958B (enExample)
MX (1) MX354249B (enExample)
MY (1) MY194947A (enExample)
NO (1) NO2706982T3 (enExample)
PH (2) PH12013502313A1 (enExample)
PL (1) PL2706982T3 (enExample)
PT (1) PT2706982T (enExample)
RS (1) RS57054B1 (enExample)
RU (2) RU2657441C1 (enExample)
SG (1) SG194927A1 (enExample)
SI (1) SI2706982T1 (enExample)
SM (1) SMT201800105T1 (enExample)
TR (1) TR201802716T4 (enExample)
TW (1) TWI486161B (enExample)
UA (1) UA110974C2 (enExample)
WO (1) WO2012156317A2 (enExample)
ZA (1) ZA201308280B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
NO2706982T3 (enExample) * 2011-05-13 2018-06-02
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
EP3777838A1 (en) * 2014-03-14 2021-02-17 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954637A1 (en) * 2014-07-09 2016-01-14 Opiant Pharmaceuticals, Inc. Co-packaged drug products
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US11559483B2 (en) * 2015-07-10 2023-01-24 Sanjay Gupta Nasal foam via cribriform plate for medication delivery to the brain and/or body and for nasal moisturization and hygiene
EP3349756A4 (en) * 2015-09-17 2019-05-15 Adapt Pharma Limited NASAL MEDICAMENT PRODUCTS AND METHOD FOR USE THEREOF
US20190209464A1 (en) * 2016-06-24 2019-07-11 Opiant Pharmaceuticals, Inc. Compositions, devices and methods for the treatment of alcohol use disorder
WO2018034920A1 (en) * 2016-08-17 2018-02-22 Insys Development Company, Inc. Liquid naloxone spray
WO2020198327A1 (en) * 2019-03-26 2020-10-01 Pocket Naloxone Corp. Devices and methods for delivering pharmaceutical compositions
EP3946547A4 (en) 2019-03-26 2023-01-18 Pocket Naloxone Corp. DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
WO2021222545A1 (en) * 2020-04-29 2021-11-04 The Texas A&M University System Naloxone nanoparticle compositions and methods thereof
HRP20221361T1 (hr) 2020-05-18 2023-01-06 Orexo Ab Novi farmaceutski sastav za davanje lijeka
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023014906A1 (en) 2021-08-04 2023-02-09 Opiant Pharmaceuticals, Inc. Compositions and methods for the treatment of opioid overdose
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9908921D0 (en) * 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
SI20850A (sl) 1999-06-16 2002-10-31 Nastech Pharmaceutical Co., Inc. Farmacevtske formulacije in postopki, ki obsegajo intranazalni morfin
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US6284765B1 (en) 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20060110333A1 (en) 2002-07-11 2006-05-25 Taiho Pharmaceutical Co., Ltd. Composition for nasal absorption
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
CN1575795A (zh) 2003-06-25 2005-02-09 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔喷雾剂
GB2403711A (en) * 2003-07-07 2005-01-12 Gw Pharma Ltd Drug dispenser with controlled access
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
CN1726915B (zh) * 2004-07-27 2013-04-24 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻腔给药系统或组合物及其制备方法
US8673360B2 (en) 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
CN100524037C (zh) * 2004-11-09 2009-08-05 皇家飞利浦电子股份有限公司 空间光调制器阵列和制造空间光调制器设备的方法
AU2005322305B2 (en) * 2004-12-23 2010-09-16 Roxro Pharma, Inc. Therapeutic compositions for intranasal administration of ketorolac
US8911751B2 (en) 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
RU2344822C2 (ru) * 2006-04-05 2009-01-27 Алексей Валентинович Надеждин Способ лечения героиновой наркомании
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
EP3150230A1 (en) * 2007-01-19 2017-04-05 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
NO2706982T3 (enExample) * 2011-05-13 2018-06-02
WO2015095644A1 (en) 2013-12-20 2015-06-25 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
EP3777838A1 (en) 2014-03-14 2021-02-17 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray

Also Published As

Publication number Publication date
EP3320893A1 (en) 2018-05-16
KR20140007482A (ko) 2014-01-17
AU2016204880A1 (en) 2016-07-28
US20190374464A1 (en) 2019-12-12
NO2706982T3 (enExample) 2018-06-02
PL2706982T3 (pl) 2018-07-31
KR101873174B1 (ko) 2018-06-29
EP2706982B2 (en) 2021-03-10
AU2016204880B2 (en) 2017-11-23
EP2706982B1 (en) 2018-01-03
JP2016128453A (ja) 2016-07-14
CN103764119A (zh) 2014-04-30
DE202012013606U1 (de) 2018-04-18
RS57054B1 (sr) 2018-05-31
PH12016501342B1 (en) 2018-06-11
TWI486161B (zh) 2015-06-01
US20240082149A1 (en) 2024-03-14
RU2657441C1 (ru) 2018-06-13
CN107260672A (zh) 2017-10-20
CY1120399T1 (el) 2019-07-10
TR201802716T4 (tr) 2018-03-21
US20170231904A1 (en) 2017-08-17
DK2706982T4 (da) 2021-05-10
LT2706982T (lt) 2018-05-25
ES2661838T5 (es) 2021-11-18
JP2018150336A (ja) 2018-09-27
IL229409B (en) 2020-10-29
DK2706982T3 (en) 2018-03-12
US20150126540A1 (en) 2015-05-07
EP2706982A2 (en) 2014-03-19
UA110974C2 (uk) 2016-03-10
RU2587051C2 (ru) 2016-06-10
DK201800034U1 (da) 2018-05-25
JP6110367B2 (ja) 2017-04-05
US20170304192A1 (en) 2017-10-26
ME02958B (me) 2018-07-20
HK1255428A1 (en) 2019-08-16
KR20170010078A (ko) 2017-01-25
ZA201308280B (en) 2014-07-30
CA2835940A1 (en) 2012-11-22
RU2013155479A (ru) 2015-06-20
WO2012156317A2 (en) 2012-11-22
AU2012257785B2 (en) 2016-04-14
SMT201800105T1 (it) 2018-05-02
HRP20180233T1 (hr) 2018-06-01
BR112013029126A2 (pt) 2017-02-07
AU2012257785A1 (en) 2013-11-28
US11806428B2 (en) 2023-11-07
US20210338574A1 (en) 2021-11-04
PT2706982T (pt) 2018-03-08
MX2013013276A (es) 2014-08-07
WO2012156317A3 (en) 2013-05-10
TW201311244A (zh) 2013-03-16
US20150018379A1 (en) 2015-01-15
AT16553U1 (de) 2020-01-15
CA2835940C (en) 2020-08-04
HUE036465T2 (hu) 2018-07-30
NZ705933A (en) 2016-07-29
CO6821959A2 (es) 2013-12-31
NZ617442A (en) 2015-03-27
AR086391A1 (es) 2013-12-11
JP2014513683A (ja) 2014-06-05
ES2661838T3 (es) 2018-04-04
MY194947A (en) 2022-12-27
SI2706982T1 (en) 2018-05-31
US12458591B2 (en) 2025-11-04
SG194927A1 (en) 2013-12-30
PH12016501342A1 (en) 2018-06-11
US11020343B2 (en) 2021-06-01
PH12013502313A1 (en) 2022-04-08
KR101698182B1 (ko) 2017-01-19
IL229409A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
MX354249B (es) Formas de dosificación farmacéuticas intranasales que comprenden naloxona.
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
CL2013001602A1 (es) Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple.
PT2601962T (pt) Regime de dosagem de lag-3 para utilização no tratamento de cancro
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
IL230819A0 (en) Refractory oral pharmaceutical dosage form containing an opioid agonist and an opioid antagonist
HK1211475A1 (en) Combination therapy
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
IL237138B (en) Pirfenidone for use in a drug given in calculated amounts
UA109781C2 (uk) Сигма-ліганди для потенціювання аналгетичного ефекту опіоїдів і опіатів при післяопераційному болю і для послаблення залежності від них
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
CL2014002790A1 (es) Metodo de prevencion o tratamiento de la disfuncion intestinal inducida por oxicodona que comprende administrar buprenorfina concomitantemente con clorhidrato de oxicodona; unidad de dosis farmaceutica; kit que comprende una unidad de dosis de buprenorfina y otra de clorhidrato de oxicodona; sistema de buprenorfina transdermico.
CL2013003198A1 (es) Uso de volasertib, una sal o un hidrato del mismo para preparar un medicamento útil en el tratamiento de malignidades sólidas que incluyen malignidades sólidas avanzadas y metastásicas.
PE20151543A1 (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso
PH12016500666A1 (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
GT201400042A (es) Compuesto de benzotiazolona
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
EP2548594C0 (en) Pharmaceutical dosage forms of intrathecal baclofen and related delivery system
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии

Legal Events

Date Code Title Description
FG Grant or registration